ScreenerHero

RGC Regencell Bioscience Holdings Limited

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · regencellbioscience.com
7.110USD-3.27%Mkt Cap: 3.52B $P/E: —

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocogn…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$66.23BUSDP/E 25.7
TAK
Takeda Pharmaceutical Company Limited
$58.68BUSD
TEVA
Teva Pharmaceutical Industries Limited
$45.70BUSDP/E 65.3
GALD
Galderma Group AG
$43.27BUSDP/E 56.1
HLN
Haleon plc
$39.67BUSDP/E 18.4
SDZ
Sandoz Group AG
$34.93BUSDP/E 60.5
HLN
Haleon plc
$32.73BUSDP/E 19.0
ZTS
Zoetis Inc.
$29.57BUSDP/E 11.8
ZOE
Zoetis Inc.
$28.56BUSDP/E 12.2
UTHR
United Therapeutics Corporation
$23.38BUSDP/E 19.5
VTRS
Viatris Inc.
$20.09BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.43BUSDP/E 112.9
NBIX
Neurocrine Biosciences, Inc.
$14.58BUSDP/E 21.0
IPN
Ipsen S.A.
$12.99BUSDP/E 23.5
ELAN
Elanco Animal Health Incorporated
$11.17BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.22BUSDP/E 27.9
KRK
Krka, d. d.
$8.66BUSDP/E 19.3
ALKS
Alkermes plc
$6.95BUSDP/E 109.1
HIMS
Hims & Hers Health, Inc.
$6.89BUSD
AMRX
Amneal Pharmaceuticals, Inc.
$6.84BUSDP/E 40.1

Key Statistics

Company
Market Cap3.52B USD
Enterprise Value3.63B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-7.05M USD
Revenue/Share—
Last Price7.110 USD
Fiscal Year EndJun 2025
MR QuarterDec 2025
Employees10
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-514.10
EV/Revenue—
P/S—
P/B3675.00
EPS (TTM)-0.01
EPS (Forward)—
52W Range
4.5104% of range69.00
52W High69.00 USD
52W Low4.510 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-177.66%
ROA-84.97%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.00M USD
CapEx (TTM)5.38K USD
FCF Margin—
FCF Yield—
Net Debt-1.97M USD
Net Debt/EBITDA0.28
Balance Sheet
Debt/Equity0.01
Current Ratio1.42
Quick Ratio1.42
Book Value/Sh0.0020 USD
Cash/Share0.0050 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split38:1
Split DateJun 16, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.494.49M
Float55.10M
Insiders88.38%
Institutions0.29%
Short Interest
Short Ratio4.3d
Short % Float1.45%
Short % Out.0.16%
Shares Short801.24K
Short (prev mo.)990.34K
Technical
SMA 505.843 (+21.7%)
SMA 20019.11 (-62.8%)
Beta1.17
S&P 52W Chg15.78%
Avg Vol (30d)170.30K
Avg Vol (10d)138.88K
Technical Indicators
RSI (14)61.8
MACD0.2531
MACD Signal0.0862
MACD Hist.+0.1670
BB Upper7.384 USD
BB Middle6.298 USD
BB Lower5.213 USD
BB Width34.48%
ATR (14)0.5764 USD
Vol Ratio (20d)0.60x